AMIODARONE TO PREVENT RECURRENCE OF ATRIAL FIBRILLATION

DENIS ROY, M.D., MARIO TALAJIC, M.D., PAUL DORIAN, M.D., STUART CONNOLLY, M.D., MARK J. EISENBERG, M.D., M.P.H., MARTIN GREEN, M.D., TERESA KUS, M.D., JEAN LAMBERT, PH.D., MARC DUBUC, M.D., PIERRE GAGNE, M.D., STANLEY NATEL, M.D., AND BERNARD TIBAULT, M.D., FOR THE CANADIAN TRIAL OF ATRIAL FIBRILLATION INVESTIGATORS*

ABSTRACT

Background The restoration and maintenance of sinus rhythm is a desirable goal in patients with atrial fibrillation, because the prevention of recurrences can improve cardiac function and relieve symptoms. Uncontrolled studies have suggested that amiodarone in low doses may be more effective and safer than other agents in preventing recurrence, but this agent has not been tested in a large, randomized trial.

Methods We undertook a prospective, multicenter trial to test the hypothesis that low doses of amiodarone would be more efficacious in preventing recurrent atrial fibrillation than therapy with sotalol or propafenone. We randomly assigned patients who had at least one episode of atrial fibrillation within the previous six months to amiodarone or to sotalol or propafenone, given in an open-label fashion. The patients in the group assigned to sotalol or propafenone underwent a second randomization to determine whether they would receive sotalol or propafenone first; if the first drug was unsuccessful the second agent was prescribed. Loading doses of the drugs were administered and electrical cardioversion was performed (if necessary) within 21 days after randomization for all patients in both groups. The follow-up period began 21 days after randomization. The primary end point was the length of time to a first recurrence of atrial fibrillation.

Results Of the 403 patients in the study, 201 were assigned to amiodarone and 202 to either sotalol (101 patients) or propafenone (101 patients). After a mean of 16 months of follow-up, 71 of the patients who were assigned to amiodarone (35 percent) and 127 of those who were assigned to sotalol or propafenone (63 percent) had a recurrence of atrial fibrillation (P<0.001). Adverse events requiring the discontinuation of drug therapy occurred in 18 percent of the patients receiving amiodarone, as compared with 11 percent of those treated with sotalol or propafenone (P=0.06).


Atrial fibrillation is the most common arrhythmia requiring treatment and affects 5 percent of people older than 65 years.1,2 The number of hospital admissions for atrial fibrillation in the United States more than doubled from 1984 to 1994, from 111,000 to 270,000.3 These numbers are probably underestimates, because many episodes of atrial fibrillation are treated on an outpatient basis or in emergency rooms, and admissions for complications such as stroke and heart failure are not necessarily attributed to atrial fibrillation.

There are multiple clinical consequences of atrial fibrillation. Patients often have disabling palpitations. In addition, the loss of effective atrial contraction may result in impaired cardiac performance, even after control of the ventricular response rate is achieved; such impairment can lead to reduced exercise tolerance and, in some patients, to congestive heart failure.4,5 Atrial fibrillation is associated with a quintupling of the risk of stroke in patients who are not receiving anticoagulant therapy and a doubling of the rate of death in all patients.6,8,10

To control symptoms, improve functional capacity, and reduce the risk of embolism, it is common practice to restore sinus rhythm; however, atrial fibrillation recurs within three to six months in at least one half of treated patients.8,11,22 The long-term use of quinidine and other class I agents for the treatment of atrial fibrillation has recently been questioned, because retrospective analyses have suggested that such agents may increase mortality.11,23 Concern about proarrhythmic effects is particularly pertinent for patients with atrial fibrillation since, by itself, atrial fibrillation is rarely fatal.

Data from several nonrandomized trials and two small, randomized trials have suggested that low-dose amiodarone may be more effective than other antiarrhythmic agents in treating atrial fibrillation22,24-29; however, the limited available results are not conclusive. We conducted a large, prospective, nonblinded, randomized trial to test the hypothesis that low-dose amiodarone is more efficacious in preventing recurrences of atrial fibrillation than antiarrhythmic therapy with sotalol or propafenone.

METHODS

Study Design

The details of the protocol have been published previously.30 The Canadian Trial of Atrial Fibrillation was conducted in 19 car-
diology centers throughout Canada. The investigational review board of each institution approved the study, and all patients gave written informed consent. Recruitment began in November 1996, randomization was concluded in February 1998, and follow-up was terminated in February 1999.

**Inclusion Criteria**

To be eligible, patients had to have had an episode of symptomatic atrial fibrillation within the preceding six months for which long-term antiarrhythmic drug therapy was planned. At least one episode of atrial fibrillation had to have lasted more than 10 minutes (determined by history taking), and electrocardiographic confirmation was required. This criterion was chosen arbitrarily in an attempt to prevent the enrollment of patients with clinically inconsequential atrial tachyarrhythmias.

**Exclusion Criteria**

The exclusion criteria were as follows: atrial fibrillation known to have been present continuously for more than 6 months, myocardial infarction during the previous 6 months, cardiac surgery during the previous 30 days, moderate or severe cardiac disability (New York Heart Association functional class III or IV), atrial fibrillation associated with an acute reversible condition, a serum creatinine concentration of more than 2.8 mg per deciliter (250 µmol per liter), a serum alanine aminotransferase concentration more than 2.5 times the upper limit of normal, chronic lung disease requiring bronchodilator therapy, the Wolff–Parkinson–White syndrome, previous long-term therapy (lasting 4 weeks or more) or intolerance of study drugs, untreated hypothyroidism, a corrected QT interval of more than 480 msec or an uncorrected QT interval of more than 500 msec in the absence of bundle-branch block, bradycardia (defined as a heart rate of less than 50 beats per minute for a period of more than one minute while the patient was awake), second-degree or third-degree atrioventricular block or a sinus pause of more than two seconds without a permanent pacemaker, an age of less than 18 years, a need for antiarrhythmic therapy for arrhythmias other than atrial fibrillation, and any medical condition that would make survival for 1 year unlikely. In addition, premenopausal women who had not undergone tubal ligation or hysterectomy were excluded.

**Randomization, Therapy, and Follow-up**

 Patients with atrial fibrillation lasting more than 48 hours had to undergo treatment with an anticoagulant agent at a dosage adjusted to achieve an international normalized ratio of 2 or more for a minimum of three weeks before randomization. After written informed consent was obtained, patients were randomly assigned to receive amiodarone or to receive sotalol or propafenone, in an open-label fashion. The patients assigned to sotalol or propafenone underwent a second randomization to determine whether they would receive sotalol or propafenone first. Loading doses of the drugs were administered and electrical cardioversion, if necessary, was performed within 21 days after randomization for the patients in both groups. Cardioversion was recommended if atrial fibrillation persisted after 14 days of loading doses of amiodarone and after 4 days of treatment with either sotalol or propafenone. If the first drug administered to a patient assigned to sotalol or propafenone was unsuccessful, the second agent was prescribed and cardioversion was reattempted. An electrocardiogram was transmitted by telephone on days 7 and 14, and patients were reevaluated in the clinic 21 days after randomization.

Amiodarone was given at a dose of 10 mg per kilogram of body weight each day for 14 days, followed by 300 mg per day for 4 weeks, after which a daily maintenance dose of 200 mg was given. Sotalol was administered as follows: 160 mg every 12 hours to men 70 years of age or younger who had a creatinine concentration of 1.5 mg per deciliter (130 µmol per liter) or less and who weighed at least 70 kg; 80 mg every 8 hours to men who were older than 70, men who had a creatinine concentration of more than 1.5 mg per deciliter, men who weighed less than 70 kg, and to women 70 or younger who had a creatinine concentration of 1.2 mg per deciliter (110 µmol per liter) or less; and 80 mg every 12 hours to women who were older than 70 or who had a creatinine concentration of more than 1.2 mg per deciliter. Propafenone was given at a dose of 300 mg every 12 hours or 150 mg every 6 hours to patients who were 70 years of age or younger and who weighed at least 70 kg; a dose of 150 mg every 8 hours was given to patients older than 70 or those who weighed less than 70 kg.

Patients were assessed by a nurse coordinator and a physician at three months and every six months thereafter. The minimal duration of follow-up was one year. Twelve-lead electrocardiograms were obtained at each visit. Chest x-ray films were obtained at 6, 12, and 24 months, and measurements of thyrotropin and alanine aminotransferase were obtained every 6 months for the patients receiving amiodarone. Patients were provided with electrocardiographic monitors capable of transmitting data over the telephone and were instructed to transmit an electrocardiogram if cardiac symptoms occurred.

The primary end point was the length of time to a first electrocardiographically confirmed recurrence of atrial fibrillation. Only episodes lasting longer than 10 minutes (as indicated by the history) were considered to be clinically significant. For the purpose of the primary end point, day 21 after randomization was considered to be the beginning of follow-up (day 0). Patients in whom sinus rhythm was not achieved within 21 days after randomization were classified as having had a recurrence on day 1. Secondary end points were adverse effects related to the study medication, thromboembolic events, and death. The system of Hinkle and Thaler was used to classify deaths. All primary outcome events and major clinical events were reviewed by a committee whose members had no other affiliation with the study and were unaware of the treatment assignments.

**Statistical Analysis**

Summary data are expressed as means ±SD or numbers and percentages of patients. Analyses were performed according to the intention-to-treat principle. Data were censored if the patient died, reached the end of the follow-up period (February 1999), or was lost to follow-up without an occurrence of the primary end point. The cumulative risk of recurrence of atrial fibrillation was estimated by the product-limit method of Kaplan and Meier, and the difference between treatment groups was assessed with the log-rank test. The Cox proportional-hazards model was used to calculate relative risk and to investigate potential differences in the effects of the study drugs among subgroups. We estimated that the enrollment of 400 patients with symptomatic atrial fibrillation would be necessary in order for the study to achieve a power of more than 0.80 to detect a reduction of 30 percentage points in the rate of recurrence of atrial fibrillation in the amiodarone group with a two-sided alpha level of 0.05, assuming a recurrence rate of 30 percent at one year in the group assigned to sotalol or propafenone and a 15 percent loss to follow-up.

**RESULTS**

A total of 403 patients were enrolled: 201 in the group assigned to amiodarone and 202 in the group assigned to sotalol or propafenone (with 101 assigned to each drug). Ten patients (2.5 percent) were lost to follow-up. Thirteen patients who were first randomly assigned to propafenone and 11 patients who were first randomly assigned to sotalol received the other drug during the 21-day period after randomization. Forty-four patients assigned to treatment with amiodarone underwent a total of 48 electrical cardioversions during the 21-day period after randomization, as compared with 63 patients assigned to treatment...
with sotalol or propafenone, who underwent a total of 84 cardioversions. Among the patients in whom electrical cardioversion was attempted, the procedure was ultimately successful in 77 percent of those assigned to amiodarone and 81 percent of those assigned to sotalol or propafenone.

Base-Line Characteristics

The clinical, electrocardiographic, and echocardiographic characteristics of the patients at the time of enrollment are shown in Table 1. With the exception of the percentage of patients with left ventricular hypertrophy, there were no significant differences in base-line characteristics between the treatment groups.

Therapy

Table 2 lists the mean daily doses of the study drugs the patients received. Table 3 lists the percentages of patients taking various concomitant medications at base line and during follow-up.

Recurrence of Atrial Fibrillation

Over the course of a mean follow-up period of 468±150 days, 71 patients assigned to amiodarone (35 percent) had first recurrences of atrial fibrillation, as did 127 of the patients assigned to sotalol or propafenone (63 percent, P<0.001). The median length of time to a recurrence was 98 days for the patients assigned to sotalol or propafenone. No median time could be calculated for the amiodarone group, because more than 50 percent of the patients in this group remained in sinus rhythm without recurrence of atrial fibrillation at the end of follow-up (therefore the median time was more than 468 days).

Figure 1A shows the actuarial probability of remaining in sinus rhythm without a recurrence of atrial fibrillation for both treatment groups. Ninety-three percent of the patients assigned to amiodarone and 81 percent of those assigned to sotalol or propafenone were in sinus rhythm at the beginning of follow-up, 21 days after randomization. The probability of remaining in sinus rhythm for one year without a recurrence of atrial fibrillation was higher among the patients assigned to amiodarone (69 percent) than among those assigned to sotalol or propafenone (39 percent, P<0.001). For the patients in the amiodarone group, the hazard ratio for a recurrence was 0.43, reflecting a 57 percent reduction in the risk of recurrence of atrial fibrillation. Similarly, when the analysis included only the 350 patients who were in sinus rhythm 21 days after randomization, the actuarial probability of remaining free of a recurrence of atrial fibrillation was significantly higher among the patients assigned to amiodarone than among those assigned to sotalol or propafenone (Fig. 1B). As Figure 1C shows, the rate of recurrence of atrial fibrillation was virtually the same for the patients assigned to sotalol and those assigned to propafenone.

**Table 1. Base-Line Clinical, Electrocardiographic, and Echocardiographic Characteristics of the Patients.**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Amiodarone (N=201)</th>
<th>Sotalol or Propafenone (N=202)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male sex (%)</td>
<td>55</td>
<td>56</td>
<td>0.81</td>
</tr>
<tr>
<td>Age (yr)</td>
<td>65±11</td>
<td>65±11</td>
<td>0.68</td>
</tr>
<tr>
<td>Medical history (% of patients)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coronary disease</td>
<td>19</td>
<td>18</td>
<td>0.68</td>
</tr>
<tr>
<td>Valvular disease</td>
<td>14</td>
<td>13</td>
<td>0.76</td>
</tr>
<tr>
<td>Hypertension</td>
<td>44</td>
<td>48</td>
<td>0.45</td>
</tr>
<tr>
<td>No cardiovascular disease</td>
<td>36</td>
<td>34</td>
<td>0.65</td>
</tr>
<tr>
<td>Diabetes</td>
<td>10</td>
<td>10</td>
<td>0.75</td>
</tr>
<tr>
<td>History of atrial fibrillation (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paroxysmal</td>
<td>49</td>
<td>43</td>
<td></td>
</tr>
<tr>
<td>Persistent†</td>
<td>51</td>
<td>57</td>
<td></td>
</tr>
<tr>
<td>Electrocardiographic findings‡</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sinus rhythm (%)</td>
<td>64</td>
<td>61</td>
<td>0.64</td>
</tr>
<tr>
<td>Atrial fibrillation (%)</td>
<td>35</td>
<td>38</td>
<td>0.56</td>
</tr>
<tr>
<td>Other rhythm (%)</td>
<td>3</td>
<td>2</td>
<td>0.72</td>
</tr>
<tr>
<td>Heart rate (beats/min)</td>
<td>75±24</td>
<td>79±26</td>
<td>0.14</td>
</tr>
<tr>
<td>Echocardiography</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left atrial dimension (mm)</td>
<td>41±7</td>
<td>41±7</td>
<td>0.66</td>
</tr>
<tr>
<td>Left ventricular ejection fraction</td>
<td>12</td>
<td>12</td>
<td>0.85</td>
</tr>
<tr>
<td>&lt;50 percent (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left ventricular hypertrophy (%)</td>
<td>13</td>
<td>21</td>
<td>0.04</td>
</tr>
<tr>
<td>Clinically significant mitral-valve or aortic-valve abnormality (%)§</td>
<td>22</td>
<td>21</td>
<td>0.75</td>
</tr>
</tbody>
</table>

*All values are means±SD. Percentages are of patients in each treatment group.
†Atrial fibrillation was defined as persistent if, in the opinion of the investigator, more than 50 percent of episodes had required intravenous drug therapy or electrical cardioversion.
‡Some patients had more than one type of rhythm.
§Clinically significant mitral-valve or aortic-valve abnormality was defined as the presence of any degree of valvular stenosis or the presence of moderate-to-severe regurgitation.

**Table 2. Mean Daily Doses of Study Drugs.**

<table>
<thead>
<tr>
<th>Study Drug</th>
<th>Day 21</th>
<th>3 Months</th>
<th>6 Months</th>
<th>12 Months</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>milligrams per day</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amiodarone</td>
<td>327±134</td>
<td>205±44</td>
<td>196±39</td>
<td>186±48</td>
</tr>
<tr>
<td>Propafenone</td>
<td>547±139</td>
<td>527±111</td>
<td>520±122</td>
<td>471±121</td>
</tr>
<tr>
<td>Sotalol</td>
<td>230±80</td>
<td>231±81</td>
<td>219±85</td>
<td>224±83</td>
</tr>
</tbody>
</table>

*All values are means±SD. Doses are reported only for the patients taking the study drug at the time in question.

**Subgroups**

Figure 2 shows the hazard ratios for the recurrence of atrial fibrillation according to a variety of dichotomous base-line, clinical, and echocardiographic characteristics. The hazard ratios did not differ significantly according to any of these variables; more-
over, all 95 percent confidence intervals included the overall hazard ratio and did not include 1.0.

Major Clinical Events

During the course of the study, nine patients assigned to amiodarone died, as compared with eight assigned to sotalol or propafenone. Four deaths were presumed to be due to arrhythmia; three of these four occurred in patients assigned to amiodarone (two of these had discontinued the drug for more than one year before death). One patient in each group died of acute myocardial infarction. One patient assigned to sotalol or propafenone died of congestive heart failure. Death was due to a vascular cause in one patient assigned to amiodarone (mesenteric infarction) and in one assigned to sotalol or propafenone (stroke). The cause of death was noncardiovascular for four patients in each group (five died of cancer, and three of other causes).

Thirty-six patients assigned to amiodarone (18 percent) were treated for a total of 45 nonfatal major clinical events, and 35 patients assigned to sotalol or propafenone (17 percent) were treated for 42 such events. Among these events, not all of which are described here, one patient receiving propafenone was resuscitated from cardiac arrest due to torsade de pointes. Congestive heart failure requiring intravenous therapy occurred in 11 patients assigned to amiodarone and 9 assigned to sotalol or propafenone. Strokes and intracranial hemorrhages were less common among the patients assigned to amiodarone than among those assigned to sotalol or propafenone (one patient vs. nine patients, P=0.01). Eight of these patients (one patient assigned to amiodarone and seven assigned to sotalol or propafenone) were receiving warfarin at the time of the event. Two patients in each group had a major hemorrhage in a location other than the nervous system. There were 7 cancers (3 among patients assigned to amiodarone and 4 among patients assigned to sotalol or propafenone) and 13 other nonfatal events (8 and 5, respectively).

Discontinuation of Study Drug

Overall, 68 of the patients assigned to amiodarone (34 percent) and 93 of those assigned to sotalol or propafenone (46 percent) stopped taking the study medication (P=0.01). Seventeen patients assigned to amiodarone (8 percent) discontinued taking the study drug because of a lack of efficacy (defined as frequent recurrences of atrial fibrillation or the need for repeated cardioversion), as compared with 56 assigned to sotalol or propafenone (28 percent, P<0.001). Fifteen patients assigned to amiodarone (7 percent) and 14 assigned to sotalol or propafenone (7 percent) were noncompliant with the study protocol or discontinued taking the medication for other reasons. Thirty-six patients assigned to amiodarone (18 percent) discontinued taking the study drug because of adverse events, as compared with 23 assigned to sotalol or propafenone (11 percent, P=0.06).

The incidence of cardiac events requiring permanent discontinuation of the study medication was similar in the two groups: ventricular tachycardia, none in the amiodarone group and one in the group assigned to sotalol or propafenone; prolongation of the QT interval, one and none, respectively; heart failure, two and three; and serious bradyarrhythmias, six and seven. The most common noncardiac adverse events responsible for discontinuation of the study medication were gastrointestinal events (eight patients in the amiodarone group and three in the group assigned to sotalol or propafenone), central nervous system events (two and one, respectively), insomnia or fatigue (six and four), and visual or dermatologic events (two and one).

Treatment with amiodarone was discontinued in four patients (2 percent) because of pulmonary abnormalities. Although amiodarone-induced pulmonary

<table>
<thead>
<tr>
<th>Medication</th>
<th>Base Line</th>
<th>3 Months</th>
<th>6 Months</th>
<th>12 Months</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMIODARONE</td>
<td>SOTALOL OR PROPafenONE</td>
<td>AMIODARONE</td>
<td>SOTALOL OR PROPafenONE</td>
<td>AMIODARONE</td>
</tr>
<tr>
<td>Percentage of Patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Digoxin</td>
<td>34</td>
<td>16</td>
<td>24</td>
<td>16</td>
</tr>
<tr>
<td>Beta-blockers</td>
<td>29</td>
<td>18</td>
<td>12</td>
<td>14</td>
</tr>
<tr>
<td>Calcium-channel blockers</td>
<td>9</td>
<td>10</td>
<td>12</td>
<td>14</td>
</tr>
<tr>
<td>Aspirin</td>
<td>23</td>
<td>24</td>
<td>27</td>
<td>27</td>
</tr>
<tr>
<td>Anticoagulant drugs</td>
<td>58</td>
<td>53</td>
<td>57</td>
<td>56</td>
</tr>
<tr>
<td>Thyroid-replacement medication</td>
<td>10</td>
<td>11</td>
<td>8</td>
<td>12</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Medication</th>
<th>Base Line</th>
<th>3 Months</th>
<th>6 Months</th>
<th>12 Months</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMIODARONE</td>
<td>SOTALOL OR PROPafenONE</td>
<td>AMIODARONE</td>
<td>SOTALOL OR PROPafenONE</td>
<td>AMIODARONE</td>
</tr>
<tr>
<td>Percentage of Patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Digoxin</td>
<td>34</td>
<td>16</td>
<td>24</td>
<td>16</td>
</tr>
<tr>
<td>Beta-blockers</td>
<td>29</td>
<td>18</td>
<td>12</td>
<td>14</td>
</tr>
<tr>
<td>Calcium-channel blockers</td>
<td>9</td>
<td>10</td>
<td>12</td>
<td>14</td>
</tr>
<tr>
<td>Aspirin</td>
<td>23</td>
<td>24</td>
<td>27</td>
<td>27</td>
</tr>
<tr>
<td>Anticoagulant drugs</td>
<td>58</td>
<td>53</td>
<td>57</td>
<td>56</td>
</tr>
<tr>
<td>Thyroid-replacement medication</td>
<td>10</td>
<td>11</td>
<td>8</td>
<td>12</td>
</tr>
</tbody>
</table>
Figure 1. Kaplan–Meier Estimates of the Percentage of Patients Remaining Free of Recurrence of Atrial Fibrillation.
Panel A shows the estimates of the proportion of patients with no recurrence of atrial fibrillation in the two groups (hazard ratio for recurrence among patients in the amiodarone group, 0.43 [95 percent confidence interval, 0.32 to 0.57]); Panel B shows the estimates for the 350 patients (187 in the amiodarone group and 163 in the group assigned to sotalol or propafenone) who were in sinus rhythm 21 days after randomization (hazard ratio, 0.45 [95 percent confidence interval, 0.32 to 0.63]); and Panel C shows the estimates for the patients who received amiodarone, those who received sotalol, and those who received propafenone. Follow-up began 21 days after randomization (designated day 0).
toxicity is difficult to prove, the diagnosis was felt to be definite in one patient and possible in three. Pulmonary toxicity was suspected in one other patient in whom pulmonary abnormalities developed two months after the discontinuation of amiodarone due to a lack of efficacy. No patient died as a result of pulmonary toxicity. Treatment with amiodarone was discontinued in two patients because of hypothyroidism and in one because of hyperthyroidism. Five patients (two assigned to amiodarone and three assigned to sotalol or propafenone) discontinued treatment because of other reasons.

**DISCUSSION**

The results of this large, randomized trial show that amiodarone is more effective than sotalol or propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation.

The difference in efficacy we observed is striking; amiodarone was about twice as effective as two commonly used antiarrhythmic agents in preventing recurrences of atrial fibrillation. Our findings indicate that amiodarone warrants consideration as first- or second-line therapy in patients in whom maintenance of sinus rhythm is desired. No difference was found in the occurrence of atrial fibrillation between the patients who received sotalol and those who received propafenone, a finding that is compatible with previous observations. Furthermore, the rates of recurrence in the patients treated with these agents in our study were very similar to those reported for patients treated with other class I drugs, such as quinidine and flecaïnide.

Amiodarone was generally well tolerated, and serious adverse events were uncommon. No proarrhythmic effect was observed among the patients assigned to amiodarone, and clinically relevant thyroid and pulmonary abnormalities occurred in a small proportion of patients.
of patients. The proportion of patients in our study who discontinued taking amiodarone because of adverse events (18 percent) was lower than that previously reported in other large trials. At one year, more patients in the amiodarone group were still receiving the drug to which they had been assigned (72 percent) than was the case in the group receiving sotalol or propafenone (58 percent). The adverse effects associated with amiodarone have usually been related to the dose and duration of therapy, and much of the concern about its use has arisen from experience with high daily doses in patients treated for ventricular tachyarrhythmias. This trial provides additional information regarding the safety of low doses of amiodarone (200 mg per day or less) for the treatment of atrial fibrillation.

Whether maintaining sinus rhythm in patients with atrial fibrillation will translate into improved survival or a reduction in the risk of thromboembolic events will require further study. Mortality was not the primary outcome measured in this trial, for several reasons. First, the absolute mortality among patients with atrial fibrillation is relatively low, and death is due primarily to associated cardiovascular diseases, making the sample needed for a study of mortality extremely large. Second, the ongoing Atrial Fibrillation Follow-up Investigation of Rhythm Management of the National Heart, Lung, and Blood Institute is comparing the mortality associated with various approaches to treating atrial fibrillation in older patients who have one or more risk factors for stroke. Finally, our study was designed to identify the most effective agent for maintaining sinus rhythm in a heterogeneous group of patients for whom the clinical decision to try to suppress atrial fibrillation had already been made. This information may help in designing subsequent trials with mortality as an end point.

Since this was a relatively short study, it did not address the potential for serious long-term adverse effects associated with low-dose amiodarone. Since the goal of this trial was to compare the relative efficacy of two treatments in patients believed by their physicians to require drug therapy for the maintenance of sinus rhythm, the use of a placebo group was deemed inappropriate. An open-label design was selected, because it would have been technically difficult to maintain blinding in a two-treatment study in which three drugs with different pharmacokinetics, pharmacodynamics, dosing regimens, and safety profiles were used. To minimize the potential effects of bias, the primary end point (recurrence of atrial fibrillation) had to be objectively confirmed by electrocardiography. In addition, all primary end points and fatal and nonfatal major events were reviewed by an independent committee, the members of which were unaware of the treatment assignments.

Overall, we found that amiodarone was more effective in preventing recurrences of atrial fibrillation than two widely used antiarrhythmic drugs. Even recognizing the limitations of the study, we believe that our results challenge the notion that amiodarone should be used only in patients whose conditions are resistant to other drugs. Since other antiarrhythmic agents are less effective and are associated with higher risks, and the safety of amiodarone with regard to cardiovascular complications is well recognized, amiodarone should be a drug of choice for patients with recurrent atrial fibrillation and structural heart disease, particularly those with left ventricular dysfunction. Amiodarone should also be considered for patients with refractory conditions who do not have heart disease, before therapies with irreversible effects, such as atioventricular-nodal ablation, are attempted. Finally, new class III antiarrhythmic agents are currently being evaluated as treatments for atrial fibrillation in placebo-controlled trials. Comparative safety and efficacy data from well-controlled studies of other accepted therapies should complement the findings of these trials. Amiodarone seems an obvious choice for such comparisons.

Supported by an operating grant from the Medical Research Council of Canada.

We are indebted to the study patients for their cooperation and to the study personnel for their assistance; to Luie Bignon for preparing the manuscript; to Dr. Jean L. Rouleau for his encouragement during the study; and to Dr. Martial G. Bourassa for his encouragement and editorial assistance.

APPENDIX

The study sites and investigators of the Canadian Trial of Atrial Fibrillation are listed below in descending order according to the number of patients randomized. For each site, the first person listed was the principal investigator:

1. Michael's Hospital and Satellite Centers (Northwestern General Hospital, Scarborough General Hospital, Scarborough Centenary Hospital, Peel Memorial Hospital, York Finch Hospital, Scarborough Grace Hospital, Etobicoke General Hospital, Humber Memorial Hospital, North York General Hospital, Toronto East General Hospital, Ottawa General Hospital, York County Hospital), Toronto: P. Dorian, D. New- man, J. Mitchell; Institut de Cardiologie de Montréal, Montreal: D. Roy, M. Talaje, M. Dubuc, B. Thibault, P. Gagné, and D. Beaudoin; Centre Hospitalier Régional de Lanaudière, Joliette, Que.: S. Konz, G.S. Ki- van, J. P. Deschamps, H. Oumet, M. Laforest, M. Roy, and C. Rémillard; Hôpital Santa Cabrini, Montreal: O. Ruscito and S. Vinci; Centre Hospitalier Le Gardeur, Repentigny, Que.: G. Gosselin, M. David, and C. Côté; University of Alberta Hospital, Edmonton, Alta.: K. Kavanaugh and R. Ta-bler; Hôpital Universitaire de Sherbrooke, Sherbrooke, Que.: R. Harvey and A. Maltais; Hôpital du Sacré-Cœur de Montréal, Montreal: T. Kus, F. Molin, and G. Gaudette; Toronto General Hospital, Toronto: E. Downar and C. Hale; Hamilton General Hospital, McMaster University, Hamilton, Ont.: S. Connolly, C. Le Feuvre, S. Kahn, and S. Morgan; Cité de la Santé de Laval, Laval, Que.: R. Gendreau and R. Couturier, Hôpital Maisonneuve-Rosemont, Montreal: D. Gossard and C. Roy; University of Ottawa Heart Institute, Ottawa, Ont.: M. Green, A. Tang, and M. Luce; Steering Committee: D. Roy (chair), M. Talaje (co-chair), M. Talaje (co-chair), P. Dorian, S. Connolly, M. Green, T. Kus, M.J. Eisenberg, A. Ciampi, and M. Morello; External Safety and Efficacy Monitoring Committee: G. Dagenais (chair), R. Nadeau, R. Roberts, and M. Tech; Validation and Events Committee: I. Dyrd (chair), J. Diolait, J. Nasmith, and N. Racine; Co-
ordinating and Methods Center: Montreal Heart Institute, Faculty of Medicine, University of Montreal, Montreal D. Roy and M. Talajic (principal investigators); B. Thibault, M. Dubuc, M. Morello, C. Dupont, A. Couturier, J. Lambert, M. J. Eisenberg, and S. Nattel.

REFERENCES


